Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024Business Wire • 09/09/24
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business UpdateBusiness Wire • 09/05/24
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 09/04/24
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialBusiness Wire • 06/17/24
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesBusiness Wire • 06/04/24
Innate Pharma Reports First Quarter 2024 Business Update and Financial ResultsBusiness Wire • 05/14/24
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateBusiness Wire • 05/07/24
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024Business Wire • 04/15/24
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsBusiness Wire • 04/15/24
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to BuyZacks Investment Research • 04/10/24
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateBusiness Wire • 04/10/24
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-FBusiness Wire • 04/05/24
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial ResultsBusiness Wire • 03/14/24